SCHEMBL1472579

SCHEMBL1472579

COCc1ccc(-c2ccc3nc(-c4ccc(Cl)cc4)cn3c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A3 P47895 8/20 0.64
ALDH1A1 P00352 4/20 0.64
RAB9A P51151 4/20 0.60
NPC1 O15118 3/20 0.60
NR4A2 P43354 6/20 0.56
KCNH2 Q12809 2/20 0.56
CYP2C9 P11712 1/20 0.56
ALDH1A2 O94788 1/20 0.52
SLC2A1 P11166 1/20 0.51
APP P05067 1/20 0.51
KDM4E B2RXH2 1/20 0.50
MAPT P10636 1/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HSD17B10 Q99714 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1472432 0.88 ALDH1A3 (0.57) ALDH1A3ALDH1A1RAB9ANPC1NR4A2
SCHEMBL1472984 0.87 NR4A2 (0.73) ALDH1A3ALDH1A1RAB9ANPC1NR4A2
SCHEMBL219888 0.82 RAB9A (0.51) ALDH1A3ALDH1A1RAB9ANPC1NR4A2
SCHEMBL1472557 0.80 NR4A2 (0.60) ALDH1A3ALDH1A1RAB9ANPC1NR4A2
Hydrochloric Acid SCHEMBL1472509 0.79 NR4A2 (0.59) ALDH1A3ALDH1A1RAB9ANPC1NR4A2
SCHEMBL13325769 0.79 ALDH1A3 (1.00) ALDH1A3ALDH1A1RAB9ANPC1NR4A2
SCHEMBL16246713 0.79 ALDH1A3 (1.00) ALDH1A3ALDH1A1RAB9ANPC1NR4A2
SCHEMBL1691409 0.76 RAB9A (1.00) ALDH1A3ALDH1A1RAB9ANPC1NR4A2
SCHEMBL13198279 0.76 RAB9A (0.73) ALDH1A3ALDH1A1RAB9ANPC1NR4A2
SCHEMBL10527726 0.76 ALDH1A3 (0.70) ALDH1A3ALDH1A1RAB9ANPC1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915284-B2 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof SANOFI-AVENTIS (FR) 2011-03-29 US claimed
EP-2069342-B1 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-05-12 EP claimed
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-10-08 US claimed
EP-2069342-B1 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-05-12 EP disclosed
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253735-A1 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF NCOR1, NR4A2, NR4A3 ALDH1A3 1043/4885ALDH1A1 1788/4885RAB9A 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.